Your browser doesn't support javascript.
loading
Intravenous immunoglobulin for patients with unexplained recurrent implantation failure: a 6-year single center retrospective review of clinical outcomes.
Peero, Einav Kadour; Banjar, Shorooq; Khoudja, Rabea; Ton-Leclerc, Shaonie; Beauchamp, Coralie; Benoit, Joanne; Beltempo, Marc; Dahan, Michael H; Gold, Phil; Kadoch, Isaac Jacques; Jamal, Wael; Laskin, Carl; Mahutte, Neal; Phillips, Simon; Sylvestre, Camille; Reinblatt, Shauna; Mazer, Bruce D; Buckett, William; Genest, Genevieve.
Afiliación
  • Peero EK; Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Bnai-Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Banjar S; Division of Clinical Immunology and Allergy, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Khoudja R; Division of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
  • Ton-Leclerc S; Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Beauchamp C; Ovo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
  • Benoit J; Obstetrics and Gynaecology Department, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada.
  • Beltempo M; Ovo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
  • Dahan MH; Obstetrics and Gynaecology Department, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada.
  • Gold P; Division of Neonatology, Montreal Children's Hospital - McGill University Health Centre, Montreal, QC, Canada.
  • Kadoch IJ; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, QC, Canada.
  • Jamal W; Department of Allergy and Immunology, Montreal General Hospital, 1650 Cedar Ave. A6-123, Montreal, QC, H3G 1A4, Canada.
  • Laskin C; Ovo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
  • Mahutte N; Obstetrics and Gynaecology Department, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada.
  • Phillips S; Clinique OVO, 8000 boulevard Décarie, Montréal, QC, H4P 2S4, Canada.
  • Sylvestre C; Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
  • Reinblatt S; TRIO Fertility, 655 Bay St, Toronto, ON, M5G 2K4, Canada.
  • Mazer BD; Deptartments of Medicine and Obstetrics & Gynecology University of Toronto, 27 King's College Cir, Toronto, ON, M5S, Canada.
  • Buckett W; The Montreal Fertility Centre, 5252 de Maisonneuve Blvd West, Suite 220, Montreal, QC, H4A 3S5, Canada.
  • Genest G; Clinique OVO, 8000 boulevard Décarie, Montréal, QC, H4P 2S4, Canada.
Sci Rep ; 14(1): 3876, 2024 02 16.
Article en En | MEDLINE | ID: mdl-38365988
ABSTRACT
The effectiveness of intravenous immunoglobulin (IVIg) for patients with unexplained recurrent implantation failure (uRIF) remains debated. We retrospectively analysed outcomes of uRIF patients treated with IVIg compared to a separate control uRIF cohort within our center (01/2014-12/2021). Primary outcomes included live birth, miscarriage, or transfer failure. We documented IVIg side effects and maternal/fetal outcomes. Logistic regression analysis was used to assess for association of IVIg exposure with outcomes and adjust for confounders. The study included 143 patients, with a 21 ratio of controls to patients receiving IVIg treatment. Patient characteristics were similar between groups. There was higher live birth rate (LBR) in patients receiving IVIg (32/49; 65.3%) compared to controls (32/94; 34%); p < 0.001). When stratifying patients into moderate and severe uRIF (respectively 3-4 and [Formula see text] 5 previous good quality blastocyst transfer failures), only patients with severe uRIF benefited from IVIg (LBR (20/29 (69%) versus 5/25 (20%) for controls, p = 0.0004). In the logistic regression analysis, IVIg was associated with higher odds of live birth (OR 3.64; 95% CI 1.78-7.67; p = 0.0004). There were no serious adverse events with IVIg. IVIg can be considered in well selected patients with [Formula see text] 5 previous unexplained, high quality blastocyst transfer failures. A randomized controlled trial is needed to confirm these findings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas Intravenosas Límite: Female / Humans / Pregnancy Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas Intravenosas Límite: Female / Humans / Pregnancy Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido